FDA Grants EUA to InflaRx’s Anti-Inflammatory COVID-19 Treatment
The FDA has granted emergency use authorization to InflaRx’s vilobelimab, now to be marketed as Gohibic, for hospitalized adult patients with COVID-19, the German biotech announced Tuesday.
FDA Grants EUA to InflaRx’s Anti-Inflammatory COVID-19 Treatment Read More »
